NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

Liu, Yan; Li, Yuyang; Liu, Shengwu; Adeegbe, Dennis O; Christensen, Camilla L; Quinn, Max M; Dries, Ruben; Han, Shiwei; Buczkowski, Kevin; Wang, Xiaoen; Chen, Ting; Gao, Peng; Zhang, Hua; Li, Fei; Hammerman, Peter S; Bradner, James E; Quayle, Steven N; Wong, Kwok-Kin

Liu, Yan; Li, Yuyang; Liu, Shengwu; Adeegbe, Dennis O; Christensen, Camilla L; Quinn, Max M; Dries, Ruben; Han, Shiwei; Buczkowski, Kevin; Wang, Xiaoen; Chen, Ting; Gao, Peng; Zhang, Hua; Li, Fei; Hammerman, Peter S; Bradner, James E; Quayle, Steven N; Wong, Kwok-Kin.

Affiliation

Liu Y; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Li Y; Shandong Provincial Hospital affiliated to Shandong University, Jinan, China.
Liu S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Adeegbe DO; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Christensen CL; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Quinn MM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Dries R; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Han S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Buczkowski K; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Wang X; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Chen T; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Gao P; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Zhang H; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Li F; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Hammerman PS; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Bradner JE; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Quayle SN; Acetylon Pharmaceuticals, Inc., Boston, Massachusetts.
Wong KK; Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. kwok-kin.wong@nyumc.org.

Cancer Res ; 78(13): 3709-3717, 2018 07 01.

Article in En | MEDLINE | ID: mdl-29760044

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Azepines/pharmacology; Histone Deacetylase 6/antagonists & inhibitors; Killer Cells, Natural/immunology; Lung Neoplasms/drug therapy; Neoplasm Recurrence, Local/drug therapy; Proteins/antagonists & inhibitors; Small Cell Lung Carcinoma/drug therapy; Triazoles/pharmacology; Animals; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Azepines/therapeutic use; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase 6/genetics; Humans; Hydroxamic Acids/pharmacology; Hydroxamic Acids/therapeutic use; Lung Neoplasms/genetics; Lung Neoplasms/pathology; Mice; Neoplasm Recurrence, Local/genetics; Neoplasm Recurrence, Local/pathology; Pyrimidines/pharmacology; Pyrimidines/therapeutic use; RNA, Small Interfering/metabolism; Small Cell Lung Carcinoma/genetics; Small Cell Lung Carcinoma/pathology; Synthetic Lethal Mutations/genetics; Treatment Outcome; Triazoles/therapeutic use; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azepines / Triazoles / Killer Cells, Natural / Proteins / Antineoplastic Combined Chemotherapy Protocols / Small Cell Lung Carcinoma / Histone Deacetylase 6 / Lung Neoplasms / Neoplasm Recurrence, Local Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Res Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google